Women can be tested for CMV prior to pregnancy – ask your doctor to run CMV IgM and IgG antibody labs. If a woman has been exposed to a recent CMV infection, it is recommended that she wait until her CMV IgM antibody levels decline to an undetectable level and her CMV IgG avidity index climbs to a highly favorable percentage before trying to conceive. This can take anywhere from six to twelve months. It is important to wait until the CMV infection has resolved because it minimizes the risk of CMV transmission from the pregnant woman to her baby in utero.
If you are already pregnant, you can request that CMV IgM and IgG antibody lab tests be added to your routine labs. These tests are relatively inexpensive and are covered by most insurance plans.
If a CMV infection is detected during pregnancy, amniocentesis is an option during which a doctor obtains and examines a sample of amniotic fluid to determine whether the baby has congenital CMV.
If you are aware that you have CMV negative status or you are unsure of your CMV status, you should learn the basic steps that can help you to reduce your risk of exposure to CMV during your pregnancy:
* Wash your hands often with soap and water for 15-20 seconds, especially after changing diapers, feeding a young child, wiping a young child's nose or saliva, and handling children's toys
* Do not share food, drinks, or eating utensils used by young children
* Do not put a child's pacifier in your mouth
* Do not share a toothbrush with a young child
* Avoid contact with saliva when kissing a child
* Clean toys, countertops, and other surfaces that come into contact with children's urine or saliva
Congenital CMV can be diagnosed if the virus is found in a baby’s urine or saliva, within 2-3 weeks from birth. Congenital CMV can only be accurately diagnosed if the newborn is tested less than 2-3 weeks after birth because, after 3 weeks, it is hard to determine if the baby could have contracted the infection through nursing or by exposure to siblings or others who may be shedding, or passing, the virus. If you find out that you became infected with CMV during your pregnancy, talk to your pediatrician about having your baby tested for congenital CMV. The testing is relatively quick, simple and painless, and is covered under most insurance policies.
Transmission of CMV is very rare through casual contact. CMV is spread by close contact with a person who has the virus in his or her saliva, urine, or other body fluids. CMV can be transmitted from a pregnant woman to her baby during pregnancy. CMV is common among healthy children one to three years of age who attend daycare and can easily spread the CMV virus among their peers. Contact with the saliva or urine of young children is a major cause of CMV infection among pregnant women, especially mothers, daycare workers, preschool teachers, therapists, and nurses.
CMV can be transmitted to an unborn child from a pregnant mother experiencing a primary or recurrent CMV infection. About 1 in 150 children is born with congenital CMV infection and about 1 of every 5 children born with congenital CMV infection will develop permanent problems CMV can cause serious disease in babies who were infected with CMV before birth (referred to as congenital CMV). Children born with congenital CMV may develop permanent medical conditions and disabilities, such as deafness, blindness, cerebral palsy, mental and physical disabilities, seizures, and death. Infants and children who are infected with CMV after birth rarely have symptoms or problems.
There is no CMV vaccine available to prevent congenital CMV. CMV vaccines are still in the research and development stage. The Institute of Medicine has ranked the development of a CMV vaccine as a highest priority because of the lives it would save and the disabilities it would prevent. Many experts believe that a CMV vaccine is possible within the next 10 to 20 years, but a CMV vaccine is unlikely to occur without the awareness and support of the general public, the pharmaceutical industry, and the federal government.
Currently, several medications are undergoing clinical trials or are licensed for the treatment and possible mitigation of the effects of congenital CMV. For pregnant women who have transmitted a primary CMV infection to their baby, administration of Cytogam, a CMV hyperimmune globulin, may lessen or reverse CMV symptoms in utero. For symptomatic newborns, both Ganciclovir and Valganciclovir have been evaluated in clinical trials and are recommended by CMV experts to treat congenital CMV disease. If you would like more information about clinical trials and CMV treatment options, speak with your doctor. If you require further support or assistance, please contact us
Cytomegalovirus (CMV) is a common infection that is usually harmless. Once CMV is in a person’s body, it stays there for life. Among every 100 adults in the United States, 50–80 are infected with CMV by the time they are 40 years old. Most children and adults infected with CMV have no symptoms and may not even know that they have been infected. Others may develop a mild illness when they get infected and have the following symptoms: fever, sore throat, fatigue, and swollen glands. But since these are also symptoms of other illnesses, most people don’t realize that they have been infected with CMV.
CMV can cause serious disease in people with a weakened immune system.
CMV is the most frequently occurring congenital viral infection in babies in the United States and is now the leading cause of non-genetic hearing loss in babies. It has been reported that this virus causes approximately one-third of all pediatric hearing loss. Hearing loss occurs in up to 75% of babies born symptomatic and 10-15% of babies born asymptomatic with congenital CMV. Hearing loss can progress throughout the course of these children’s lives, even into young adulthood. Hearing evaluations should be performed on a regular basis to detect hearing loss and its progression, and regular speech and language therapy should be a part of a child’s ongoing curriculum.
Babies born with congenital CMV can have widely diverse outcomes, and it is difficult to predict with any degree of certainty their future health or developmental prognosis.
Babies born with congenital CMV may be born with birth defects and developmental disabilities, including:
• Hearing loss
• Vision loss
• Mental disability
• Microcephaly (small head or brain)
• Intracranial calcifications
• Lack of coordination
• Cerebral Palsy
• Feeding issues / Failure to Thrive (FTT)
• Sleeping, Behavior, Sensory issues
• Death (in rare cases)
Babies born with congenital CMV can appear to be either symptomatic or asymptomatic at birth.
In short, there is disparity between recommendations by the Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists (ACOG), and actual clinical practice among OB/GYNs. In the United States, congenital CMV occurs in approximately 1 in 150 births, leading to permanent birth defects and developmental disabilities (including hearing loss, vision loss, and cognitive impairment) in approximately 1 in 750 children. Because a CMV vaccine is not yet available and treatment options are limited, renewed attention has been given to prevention of CMV infections among pregnant women through traditional infection-control practices, such as good hand hygiene. These hygienic practices have been encouraged by the CDC and ACOG, but recent studies show that very few OB/GYNs report counseling their patients about preventing CMV during pregnancy. These results emphasize the need for additional training of OB/GYNs regarding CMV infection prevention and for a better understanding of the reasons that physician knowledge regarding CMV transmission might not result in-patient counseling.